Home
 /
Papers
 /
Genomics
 /
A telomere-to-telomere map of somatic mutation burden and functional impact in cancer
Preprint
Open access
V1
Top 1% · Validated by QED

A telomere-to-telomere map of somatic mutation burden and functional impact in cancer

Min-Hwan Sohn, Danilo Dubocanin, Mitchell R Vollger +38 more
October 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.10.10.681725
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Genomics this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

The first telomere-to-telomere diploid cancer genome reveals that 16% of somatic variants are invisible to standard references, overturning assumed completeness of cancer genomics and establishing satellites, centromeres, and telomeres as functional hotspots of tumor evolution.

QED claims analysis

Summary

Telomere-to-telomere diploid genome assembly of a melanoma and matched normal sample reveals that 16% of somatic variants occur in sequences absent from standard references, with satellite repeats serving as major hotspots for UV-induced mutagenesis due to sequence-intrinsic mutability, centromere kinetochore domains undergoing extensive genetic and epigenetic remodeling, telomeres experiencing punctuated cycles of attrition and telomerase-mediated extension, and copy number alterations plus epimutations—rather than point mutations—predominantly rewiring cancer gene regulatory programs.

See full analysis
Main Claim 1 –

T2T Diploid Assemblies Enable Somatic Variant Detection in Complex Regions

Supporting evidence

  • Kinetochore Breakpoints Show Kataegis with Minimal Microhomology
Main Claim 2 –

Sixteen Percent of Somatic Variants Lie Outside GRCh38

Main Claim 3 –

Satellite Repeats Accumulate UV Mutations via Mutability and Poor Repair

Supporting evidence

  • Kinetochore Regions Mutate More and Epigenetically Reorganize in Cancer
Main Claim 4 –

Cancer Telomeres Show Punctuated Attrition and Telomerase Extension Cycles

Abstract

Oncogenesis involves widespread genetic and epigenetic alterations, yet the full spectrum of somatic variation genome-wide remains unresolved. We generated a near-telomere-to-telomere (T2T) diploid assembly of a donor paired with deep short- and long-read sequencing of their melanoma. This revealed that 16% of somatic variants occur in sequences absent from GRCh38, with satellite repeats acting as hotspots for UV-induced damage due to sequence-intrinsic mutability and inefficient repair. Centromere kinetochore domains emerged as focal sites of structural, genetic, and epigenetic variation, leading to remodeling of centromere kinetochore binding domains during tumor evolution. Single-molecule telomere reconstructions uncovered cycles of attrition, deletion, and telomerase-mediated extension that shape cancer telomeres. Finally, diploid chromatin maps exposed that copy number alterations and epimutations, rather than point mutations, predominate in rewiring cancer regulatory programs. These findings define the full landscape of a cancer’s somatic variation and their functional impact, establishing a blueprint for T2T studies of mosaicism.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?